{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:32:02Z","timestamp":1758274322298},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.025","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T06:04:58Z","timestamp":1254204298000},"page":"S286-S292","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S3","title":["Progress in Myelodysplastic Syndromes"],"prefix":"10.3816","volume":"9","author":[{"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.025_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jncimonographs\/lgn014","article-title":"NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men","volume":"39","author":"Slape","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.3816\/CLM.2009.s.025_bib4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/leu.2008.361","article-title":"Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome","volume":"23","author":"Lopez-Villar","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.025_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","article-title":"Cytogenetic features in myelodysplastic syndromes","volume":"87","author":"Haase","year":"2008","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.s.025_bib6","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2141.2008.07245.x","article-title":"Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review","volume":"142","author":"Bernasconi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.025_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q-syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.025_bib9","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients","volume":"104","author":"Pellagatti","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.s.025_bib10","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0050035","article-title":"An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome","volume":"5","author":"Ebert","year":"2008","journal-title":"PLoS Med"},{"key":"10.3816\/CLM.2009.s.025_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib12","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.025_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"10.3816\/CLM.2009.s.025_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/asheducation-2007.1.405","article-title":"Modifying the epigenome as a therapeutic strategy in myelodysplasia","volume":"2007","author":"Garcia-Manero","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.3816\/CLM.2009.s.025_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib16","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2008.130","article-title":"Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia","volume":"22","author":"Kuang","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.025_bib17","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2007-03-079673","article-title":"Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes","volume":"110","author":"Mohamedali","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib18","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.025_bib19","first-page":"18","article-title":"The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD","volume":"1","author":"Vardiman","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib20","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.025_bib22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.025_bib23","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2008.153","article-title":"Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes","volume":"23","author":"Kuendgen","year":"2009","journal-title":"Leukemia"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.025_bib25","first-page":"395s","article-title":"Cause of death in lower risk myelodysplastic syndrome","volume":"26","author":"Conley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.6004\/jnccn.2008.0069","article-title":"Myelodysplastic syndromes","volume":"6","author":"Greenberg","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLM.2009.s.025_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","article-title":"Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality","volume":"78","author":"Takatoku","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.025_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V112.11.640.640","article-title":"Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome","volume":"112","author":"Sanz","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib29","first-page":"78a","article-title":"Improved survival in patients with myelodysplastic synsdromes (MDS) receiving iron chelation therapy","volume":"118","author":"Leitch","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib30","doi-asserted-by":"crossref","first-page":"80a","DOI":"10.1182\/blood.V110.11.249.249","article-title":"Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A Prospective analysis by the GFM","volume":"110","author":"Rose","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"Jadersten","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib32","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib33","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.025_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.025_bib36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.025_bib37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib38","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study","volume":"113","author":"Ades","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.3816\/CLM.2009.s.025_bib40","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib41","doi-asserted-by":"crossref","first-page":"250a","DOI":"10.1182\/blood.V110.11.817.817","article-title":"Azacitidine treatment prolongs overall survival in higher risk MDS patients compared with conventional care regimens: Results of the AZA-001 phase III study","volume":"110","author":"Fenaux","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib42","doi-asserted-by":"crossref","first-page":"707a","DOI":"10.1182\/blood.V106.11.2517.2517","article-title":"Azacytidine (Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes","volume":"106","author":"Lyons","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.025_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib45","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.025_bib46","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib48","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.025_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood.V112.11.226.226","article-title":"Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups","volume":"112","author":"WijerMans","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.025_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/07357900500283119","article-title":"Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents","volume":"23","author":"Garcia-Manero","year":"2005","journal-title":"Cancer Invest"},{"key":"10.3816\/CLM.2009.s.025_bib53","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Kuendgen","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib54","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib55","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","article-title":"Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia","volume":"112","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib56","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","article-title":"Antileukemia activity of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid","volume":"29","author":"Yang","year":"2005","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.025_bib58","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib59","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib60","doi-asserted-by":"crossref","first-page":"137a","DOI":"10.1182\/blood.V110.11.444.444","article-title":"Phase I\/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)","volume":"110","author":"Garcia-Manero","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood.V112.11.228.228","article-title":"Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML","volume":"112","author":"Issa","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.025_bib62","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.025_bib63","doi-asserted-by":"crossref","unstructured":"Jabbour E, Garcia-Manero G, Shan J, et al. Outcome of patients (pts) with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post decitabine failure. Blood 112; 112:1659.","DOI":"10.1182\/blood.V112.11.1659.1659"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T11:47:13Z","timestamp":1590148033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":63,"alternative-id":["S1557919011703535"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.025","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}